Oct 12, 2020 01:40 PM

Chinese Biotech Firm Everest Medicines Raises $451 Million in Hong Kong IPO

Photo: CBC Group
Photo: CBC Group

(Deal Street Asia) — Everest Medicines Ltd., a Chinese clinical-stage biopharmaceutical firm created by CBC Group, has raised almost HK$3.5 billion ($451.6 million) in an initial public offering (IPO) in Hong Kong on Friday.

The China-based biotech company offered a total of 63.5 million ordinary shares at a price of HK$55 apiece, the upper end of the firm’s proposed range between HK$50 and HK$55.

Everest Medicines, which had filed for the IPO this July, develops a portfolio of eight clinical-stage drug candidates across oncology, immunology, cardiorenal disease, and infectious disease to address unmet medical needs, initially in China and emerging Asia Pacific markets.

As the firm has yet to generate any revenue, its net operating losses stood at 127.2 million yuan ($19 million) and 176.1 million yuan ($26 million) in 2018 and 2019. It is expected to create revenue from product sales after it obtains regulatory approval and commercialize one of its current or future drug candidates.

Everest Medicines was founded in July 2017 by CBC Group, a health care-focused private equity firm that invests across pharmaceuticals, biotech, medical technology and health care services.

“This [Everest’s IPO] is not just a milestone for Everest, but also one for CBC,” said Fu Wei, CEO of CBC Group and chairman of Everest Medicines. “… and we look forward to continuing to support them as they look to transform China’s burgeoning biotech industry.”

Asia-focused CBC Group had also cofounded I-Mab Biopharma Co. Ltd., a Chinese late-stage biotech firm that went public in a $104-million Nasdaq IPO this January, and U.S.-based small molecule medicines developer NiKang Therapeutics. It had backed Chinese hematology hospital group Lu Daopei Medial Group and Anrei Group, a provider of medical devices for minimal invasive surgeries in China.

Everest Medicines intends to use the majority of the net proceeds of about HK$3.13 billion to fund ongoing and planned clinical trials, preparation for registration filings, and commercialization of four anchor products.

The firm will also use part of the capital to support business development activities and the expansion of its drug pipeline, among others. Before the listing, Everest had closed $310 million in a series C round across two preferred equity financing tranches in June, including a $260-million series C2 round and a $50-million series C1 round.

The series C2 round was led by Hong Kong-based Janchor Partners and co-led by Boston-based multi-stage investment manager RA Capital Management, and Asia-focused PE major Hillhouse Capital, while the series C1 round consisted of a $50 million investment from Chinese state-owned investor Jiashan SDIC.

Goldman Sachs (Asia), Merrill Lynch (Asia Pacific), Citigroup Global Markets Asia, China International Capital Corp (CICC), Nomura International (Hong Kong) and others served as the underwriters of the deal. Everest’s shares are listed under the symbol “1952.”

This story was first published in Deal Street Asia.

Download our app to receive breaking news alerts and read the news on the go.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code